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PEMBANGUNAN DAN PENILAIAN MIKROSFERA TERBIODEGRADASI 
BERMUATAN TERBUTALIN SULFAT UNTUK PENGHANTARAN 
PULMONARI  
 
 
ABSTRAK 
 
Mikrosfera terbutalin sulfat (TBS) pelepasan tertahan dibangun menggunakan 
polimer PLA R 203H dan PLGA RG 504H. Mikrosfera disediakan menggunakan 
kaedah emulsi berganda pemeruapan pelarut dan amaun TBS terperangkap 
dalam mikrosfera ditentukan dengan spectrometer UV. Pengaruh surfaktan 
(PVA dan natrium oleat) dan gelatin di dalam fasa luar dan pH di dalam fasa 
internal ke atas ciri-ciri fizikal mikrosfera dikaji. PVA (0.5 and 5%), natrium oleat 
(0.1 and 0.5%) dan pH (4, 5.8 and 7.4) didapati mempengaruhi ciri-ciri fizikal 
(saiz, hasil, muatan drug dan kecekapan pemerangkapan) mikrosfera. 
Sebaliknya, gelatin (25, 50 and 100 mg) tidak ada kesan terhadap ciri-ciri fizikal 
mikrosfera PLA dan PLGA. Pada keadaan optimum (PVA 0.5%, natrium oleat 
0.1% and pH 7.4) muatan drug, kecekapan pemerangkapan, hasil dan purata 
saiz partikel adalah 0.85%, 34.99%, 87.11% dan 6.55 µm masing-masing untuk 
PLA dan 0.76 %, 31.17 %, 84.52% dan 8.64 µm masing-masing untuk PLGA. 
Profil terma DSC memperlihatkan Tg mikrosfera PLA dan PLGA berganjak ke 
nilai rendah. Tambahan pula, spectrum FTIR juga memperlihatkan anjakan ciri-
ciri puncak TBS di dalam mikrosfera. Ini menunjukkan interaksi molekul telah 
berlaku di antara TBS dengan polimer di dalam mikrosfera. Imbasan mikroskop 
electron memperlihatkan struktur permukaan mikrosfera PLA lebih berliang 
daripada PLGA. Tambahan pula, pelepasan drug dari mikrosfera PLA lebih 
cepat dari pada PLGA. Penambahan gelatin ke dalam formulasi didapati 
memanjangkan pelepasan drug dari mikrosfera. Pelepasan drug pada fasa 
cepat peringkat awal (6 jam) dari PLA dan PLGA tanpa gelatin masin-masing 
adalah 76.31% and 55.4% dan selebihnya dibebaskan dalam masa 24 jam and 
72 jam. Sebaliknya, pelepasan drug pada fasa cepat peringkat awal dari PLA 
dan PLGA dengan gelatin masing-masing adalah 35.4% and 22.4% dan 
selebihnya dibebaskan dalam masa 144 jam dan > 144 jam. Pelepasan drug 
dari mikrosfera PLA dan PLGA tanpa gelatin mengikut kinetik tertib pertama. 
Walaubagaimanapun, pelepasan drug dari PLA dan PLGA dengan gelatin 
masing-masing mengikut kinetik Higuchi dan bi-eksponential tertib pertama. 
Purata saiz aerosol (MMAD) PLA terhidrat semula (2.53 µm) dan PLGA 
terhidrat semula (3.50 µm) yang dihasilkan menggunakan nebulizer lebih kecil 
daripada MMAD PLA (11.10 µm) dan PLGA (11.47 µm) yang dihasilkan oleh 
Rotahaler. Sebagai tambahan, FPF dari PLA (49.54%) and PLGA (37.50%) 
yang dihasilkan oleh nebulizer lebih tinggi daripada FPF dari PLA (11. 89%) 
and PLGA (10.57%) yang dihasilkan oleh Rotahaler. Sebagai kesimpulan, 
mikrosfera bermuatan TBS adalah formulasi yang terbaik untuk TBS pelepasan 
tertahan penghantaran pulmonari menggunakan nebulizer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
DEVELOPMENT AND EVALUATION OF TERBUTALINE SULPHATE 
LOADED-BIODEGRADABLE MICROSPHERES FOR PULMONARY 
DELIVERY. 
 
 
 
ABSTRACT 
 
Sustained-release terbutaline sulphate (TBS) microspheres were developed 
using PLA R 203H and PLGA RG 504H polymers. The microspheres were 
prepared using the double emulsion solvent evaporation method and the 
amount of TBS entrapped in the microspheres was determined by UV 
spectrometry. The influence of surfactants (PVA and sodium oleate) and gelatin 
in the external phase and the pH in internal phase on the physical 
characteristics of the microspheres were investigated. PVA (0.5 and 5%), 
sodium oleate (0.1 and 0.5%) and pH (4, 5.8 and 7.4) were found to influence 
the physical characteristics (size, yield, drug loading and entrapment efficiency) 
of the microspheres. Conversely, gelatin (25, 50 and 100 mg) had no effect on 
the physical characteristics of both PLA and PLGA microspheres. At optimum 
level (PVA 0.5%, sodium oleate 0.1% and pH 7.4) the drug loading, entrapment 
efficiency, yield and mean particles size of PLA were 0.85%, 34.99 %, 87.11% 
and 6.55 µm while that of PLGA were 0.76%, 31.17%, 84.52% and 8.64 µm 
respectively. The DSC thermal profiles revealed that the Tg of PLA and PLGA 
microspheres shifted to a lower value when TBS incorporated into 
microspheres. Moreover, the FTIR spectra also showed a shift in the 
characteristic peak of TBS in microspheres. This indicates that molecular 
interaction had occurred between TBS and polymers within the microspheres. 
The scanning electron microscope revealed that the surface structure of PLA 
was more porous than that of PLGA microspheres. Furthermore, the release of 
drug from PLA microspheres was faster than from PLGA microspheres. An 
addition of gelatin to the formulation was found to prolong the release of drug 
from the microspheres. Drug release at the initial rapid phase (6 h) from PLA 
and PLGA without gelatin was 76.31% and 55.4% respectively while the 
remaining amount was released within 24 h and 72 h respectively. In contrast, 
drug release at the initial rapid phase from PLA and PLGA with gelatin was 
35.4% and 22.4% respectively while the remaining amount was released within 
144 h and >144 h respectively. The drug release from both PLA and PLGA 
microspheres without gelatin fitted first order release kinetics model. However, 
drug release from PLA and PLGA with gelatin followed the Higuchi and bi-
exponential first order release kinetics models respectively. The mean aerosols 
size (MMAD) of rehydrated PLA (2.53 µm) and rehydrated PLGA (3.50 µm) 
generated using nebulizer were smaller than the MMAD of PLA (11.10 µm) and 
PLGA (11.47 µm) produced by a Rotahaler. In addition, the fine particle fraction 
(FPF) of PLA (49.54%) and PLGA (37.50%) aerosolized by a nebulizer were 
higher than the FPF of PLA (11.89%) and PLGA (10.57%) produced by a 
Rotahaler. In conclusion, TBS- loaded PLA microspheres is a promising 
candidate for pulmonary delivery of sustained-release TBS using a nebulizer. 
 
 
 
 
CHAPTER 1: GENERAL INTRODUCTION 
 
1.1 RESPIRATORY SYSTEM 
The human respiratory system is a complicated organ system of very close 
structure-function relationships. The system consists of two regions: the 
conducting airway and the respiratory region. The airway is further divided into 
many folds: the nasal cavity and the associated sinuses; the nasopharynx, 
oropharynx, trachea, bronchi and bronchioles. The respiratory region consists of 
respiratory bronchioles, alveolar ducts and alveolar sacs (Travis et al., 1999).  
 
Beta2-adrenergic receptors exist throughout the airways such as on the 
epithelium, smooth muscle, alveoli and specialized cell types including on the 
Clara and mucus-secreting cells (Nijkamp, 1993). The existence of epithelial β2 
-receptors is of particular importance to respiratory function, as it mediates 
various functions in man and animals including smooth muscle relaxation, 
clearance of alveolar fluid, influence of ion fluxes, as well as modulating the 
release of bronchodilating mediators (Abraham et al., 2003).  
 
The respiratory system has very efficient defence and clearance mechanisms 
for foreign particles and infectious agents inhaled on inspiration. The nose traps 
almost all particles with an aerodynamic diameter of more than 5 µm (Fig 1.1). 
Aerodynamic diameter refers to the way particles behave in air rather than to 
their actual size. The mucociliary blanket of the airway epithelium disposes of 
particles with an aerodynamic diameter 3-5 µm. The ciliary beat drives the 
mucous blanket toward the trachea, and particles that land on the mucociliary  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Deposition of particles in the respiratory tract (adapted from Travis 
et al., 1999).  
 
 
blanket of the airway epithelium are thus removed from the lungs and 
swallowed or coughed up. Alveolar macrophages protect the alveolar space by 
phagocytizing viable and non-viable particles which have aerodynamic diameter 
less than 2 µm. Very small particles that behave like gas are not phagocytosed 
but exhaled (Travis et al., 1999). Nevertheless, Everard (2003) reported that by 
generating airborne particles in 1-5 µm range they were able to exploit a relative 
weakness in the pulmonary defence mechanisms and deposit foreign materials 
relatively effectively in the lung. 
  
 
1.2 ASTHMA 
 
Asthma is a heterogeneous common chronic condition characterized by 
endobronchial inflammation with consequent bronchial hyperesponsiveness 
(Currie et al., 2005). This leads to variable airflow obstruction and typical 
symptoms such as cough, breathlessness, chest tightness, wheezing and 
reduced exercise tolerance. The precise aetiology of asthma remains uncertain, 
but genetic and environmental factors such as viruses, allergen exposure, early 
use of antibiotics, and the numbers of siblings have all been implicated in its 
inception and development (Sandford et al., 2000). 
 
1.2.1 Drugs used for treatment of asthma 
Beta2-adrenoceptor agonists and glucocoticoids are at present the most 
effective drugs for the treatment of airway obstruction and inflammation, with 
theophylline, leukotriene receptor antagonists and anticholinergics functioning 
as second- or third-line therapy. For decades, there has been no newly 
developed drug available to supplement or even replace beta2-adrenoceptor 
 agonists or glucocorticoids (Rabe and Schmidt, 2001). However, a 
combination therapy consisting of inhaled corticosteroids and long acting 
beta2-adrenoceptor agonists (single-inhaler combination product) e.g. 
budesonide/formoterol and salmeterol/fluticasone can be considered as a new 
addition to the pharmacological management of asthma (Balanag et al., 
2006). Recently, efforts have been made to develop a dry powder inhalation 
system consisting of vasoactive intestinal peptide analogue (IK312532-DPI) to 
treat pulmonary diseases such as asthma (Ohmori et al., 2006). 
 
1.2.1(a) Bronchodilators 
Beta2-adrenoceptor agonists such as salbutamol and terbutaline have been 
the standard therapies for the symptomatic treatment of asthma (Mohammed 
et al., 2000). At present, good clinical and experimental experience with short 
(e.g. fenoterol, salbutamol and terbutaline) and long acting (e.g. salmeterol 
and formoterol) beta2-adrenoceptor agonists seems to suggest that it is rather 
unlikely that novel bronchodilators which are better tolerated and more 
effective will be developed. Beta2-adrenoceptor agonists are believed to 
cause airway smooth muscles to relax by increasing intracellular levels of 
cyclic adenosine monophosphate and opening potassium channels. Attempts 
have been made to imitate these effects with other substances such as 
nonselective phosphodiesterase inhibitors and potassium channel openers. 
However, these drugs were shown to be far less effective as bronchodilators 
compared to beta2-adrenoceptor agonists, and their application at higher 
doses in order to cause smooth muscle relaxation was limited with marked 
side-effects (Rabe and Schmidt, 2001).  
 1.2.1(b) Anti-inflammatory drugs  
Airway tissue inflammation is considered to be the main mechanism in the 
development and maintenance of asthma. So, limiting exposure to 
inflammatory  
triggers and reducing the inflammatory process using anti-inflammatory drugs 
are the main thrusts in the management of asthma. The first-line anti-
inflammatory drugs of inhaled corticosteroids (e.g. budesonide, 
beclometasone dipropionate, flunisolide and fluticasone), may be adequate to 
fully control symptoms in mild cases (Sears and Lotvall, 2005). However, for 
many patients, additional drug therapy, typically long acting beta2-
adrenoceptor agonists that relax the smooth muscle in the airway, is needed 
for long term treatment of moderate to severe asthma (Barnes, 2006; Sin and 
Paul Man, 2006). 
 
1.2.1(c) Cromones and other drugs  
Cromones including disodium cromoglycate and nedocromil have been used 
in the treatment of asthma for many years. Clinical trials in children and adults 
with asthma have shown that inhaled corticosteroids (such as fluticasone 
propionate) and cromones (such as nedocromil) alleviate asthma symptoms, 
lung dysfunction and decrease nonspecific bronchial hyperreponsiveness 
(Vatrella et al., 2002). In addition, other drugs such as methylxanthines, 
leukotriene receptor antagonists, anti-cholinergics and antihistamines have 
also been used in the treatment of asthma. 
 
 
 1.2.2 TREATMENT OF ASTHMA VIA INHALATION AEROSOLS 
Aerosols are an effective method to deliver therapeutic agents to the 
respiratory tract (Sham et al., 2004). Nebulizers, metered dose inhalers, or dry 
powder inhalers are commonly used for this purpose (Cohn et al., 2003; Dalby 
and Suman, 2003). 
 
1.2.2(a) Nebulizers 
A nebulizer is a device designed for the purpose of producing an aerosol (Fig 
1.2).  The device works by converting liquid asthma medication into aerosol 
droplets. The droplets are then inhaled into the lower respiratory tract through 
a mask worn over the nose and mouth of a patient. Nebulizers can be 
classified into two categories namely, jet nebulizers and ultrasonic nebulizers. 
Several advantages of nebulizers have been reported:  
 Some patients like infants, young children and elderly patients cannot 
master the coordinated effort needed to correctly use the metered dose 
inhaler, or dry powder inhalers (O´Driscoll, 1997).  
 Some patients feel more comfortable using nebulizers, enjoying the 
way the mist feels in their lungs (Win and Hussain, 2005).  
 The inhaled droplets produced by nebulizers may alter the mucus 
viscosity in the airways and a nebulized drug or saline solution may 
help patients with bronchiectasis to expectorate (Sutton et al., 1988). 
 
Although the use of nebulizers is encouraging, nebulizers exhibit certain 
disadvantages in that they are cumbersome to use and costly.  
 
  
 
 
Figure 1.2 Example of an Air jet nebulizer (adapted from Dalby and Suman,  
2003). 
 
 
 
 
 
 
 
 
 
 
 
 1.2.2(b) Metered dose inhalers (MDIs) 
Metered dose inhalers are a well-known dosage form for treatment of 
respiratory diseases (Fig 1.3). Aerosolized beta agonists and anti-allergic 
compounds were first formulated as pharmaceutical aerosols in 1956 using 
chlorofluorocarbons (CFCs). The MDI formulation comprises an active 
ingredient and one or more propellants. In addition, it may also contain 
formulation additives, such as surfactants and co-solvents. The propellant 
system is the main ingredient in MDI formulations and serves as a solvent and 
dispersion medium for drug substance and other excipients. It also serves as 
an energy source for generating an aerosol cloud on actuation while the dose 
is emitted from the metering valve (Williams et al., 1998). 
 
CFC propellants possess several desirable characteristics that have made 
them an excellent choice for use as metered dose inhaler propellants. They 
are chemically stable and as a result, are not metabolized but are instead 
rapidly re-emitted into the atmosphere when the patient exhales. CFC 
propellants offer the additional advantage of extremely low toxicity and are not 
flammable at atmospheric pressure and temperatures (Kempsford et al., 
2005). Moreover, they are inexpensive to produce and have been widely 
available since the 1970s. However, scientific research has unearthed 
substantial evidence that CFCs and other chlorine-containing chemicals 
contribute to the depletion of the stratospheric ozone layers (Molina and 
Rowland, 1974). CFCs production in the United States came to a virtual stop 
on January 1, 1996, when the use of CFC in air-conditioning, refrigeration and  
  
 
Figure 1.3 Basic components of a pMDI (adapted from Smyth, 2003). 
 
 
 
 
 
 
 
 
 
 
 
 production of foam was phased out. However, production of pharmaceutical-
grade CFCs for use in MDIs, has continued. This is because MDIs are 
considered essential for the health of patients with asthma and chronic 
obstructive pulmonary disease. Efforts have been made to consider an 
alternative to ozone-depleting CFC using other classes of environmental 
friendly propellant such as hydrofluroalkanes (HFAs). For instance, HFAs 
propellants (e.g. HFA-133a and HFA-227) have been recommended to be 
used in the delivery of inhaled medication. This is because in most cases, 
HFAs meet safety standards and are found to be as effective as their 
predecessor, the CFC propellant. As a result, many MDIs containing CFC 
were replaced by HFAs for example salmeterol (Chopra et al., 2005).  
 
1.2.2(c) Dry powder inhalers (DPIs) 
The requirement to replace ozone-depleting CFCs propellants, has led to the 
pharmaceutical industry re-evaluating the potential of dry powder inhalers. 
However, the delivery efficiency of DPI currently is not high, as in some cases 
only 7-30% of the inhaled dose of the drug are deposited in the lung 
depending upon the devices or brands used (i.e. Spinhaler®, Diskhaler®, 
Rotahaler® (Fig 1.4), Turbuhaler® and Novolizer®) (O´connor, 2004). The site 
of deposition and deposition patterns of the inhaled aerosol from DPIs are 
influenced by two major interdependent factors: (a) the patient (anatomical 
and physiological aspects of the respiratory tract as well as mode of 
inhalation) and (b) the physical properties of the aerosol cloud (Timsina et al., 
1994). However, dry powder inhaler posses several advantages over other 
delivery methods. They are propellant-free, portable, easy to operate and low-  
  
 
 
 
 
Figure 1.4 Schematic diagram of the Rotahaler device (adapted from Chew et 
al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 cost devices. Moreover, the stability of the formulation is improved as a result 
of the dry state (Bosquillon et al., 2001). 
 
1.3 ADVANTAGES OF PULMONARY DRUG DELIVERY 
The pulmonary route of drug administration delivers adequate therapeutic 
levels of potent bronchodilators in respiratory tract and provides a better 
clinical response whilst reducing their distribution to other organs (Lai et al., 
1993). This route provides an excellent example of targeted drug therapy. 
Indeed, aerosol delivery has long been viewed as a promising technique in 
the treatment of lung cancer (Koshkina et al., 2003).  
 
The lung has a large surface area (up to 100 m²), thin absorptive barrier, low 
enzymatic metabolic activity, and good blood supply. These characteristics 
make the lung an attractive target for the non-invasive administration of 
aerosolized systemically-active peptide and protein drugs (Yamamoto et al., 
2005).  
  
The pulmonary delivery route as well as nasal, rectal, and oral routes, have 
attracted much attention, in attempts to improve the quality of patients lives, 
because no repeated injections are required (Kawashima et al., 1999). 
Contrary to the oral route of drug administration, pulmonary inhalation is not 
subject to first pass metabolism. Therefore, expensive biotechnology drugs 
like toxic chemotherapeutics are ideal drug candidates for local pulmonary 
administration (Sharma et al., 2001).  
 
 The main advantage of the treatment of the respiratory tract diseases via 
inhalation aerosols therapy is that a relatively low drug concentration reaches 
systemic circulation. Consequently, the intensity and incidence of the side 
effects of inhaled drugs is, in many instances, markedly reduced compared to 
administration via the oral route (Tsapis et al., 2003).  
 
Several drugs such as bronchodilators, anti inflammatory agents, mucolytics, 
anti viral agents, antibiotics agents, and pentamidine are all routinely given as 
aerosolized formulations (BNF 43, 2002). In addition, a number of drugs for 
example insulin, cyclosporin, interferon, antitrypsin, protease inhibitors, 
deoxyribonucleases, recombinant adenoviruses and others have been 
reported to have high potential for delivery via the respiratory route (Waldrep 
et al., 1998; Karathanasis et al., 2005). 
 
1.4 SUSTAINED RELEASE MICROSPHERES FOR PULMONARY DRUG  
       DELIVERY  
The advantages of sustained release drug delivery to the respiratory tract are 
numerous. They include extended duration of action, reduction in drug use, 
improved management of therapy, improved compliance and reduction in side 
effects (Zeng et al., 1995). Moreover, lower dosage regimens may provide 
considerable cost savings especially those that involve expensive therapeutic 
agents (Saks and Gardner, 1997). A number of methods have been 
investigated as potential pulmonary sustained release systems for short acting 
drugs. These include the incorporation of drugs in liposomes and other 
biodegradable microspheres (Zeng et al., 1995).    
 The efficacy of a liposomal sustained release delivery system to the 
respiratory tract has been proven by Juliano and McCullough (1980). They 
showed that the chemotherapeutic agent, arabinoside entrapped within 
liposomes had a longer half-life of release in the lungs than did a free drug (8 
versus 1 h, respectively).  
 
Furthermore, retention of liposomes within the lung provided more specific 
pharmacological activity and minimized systemic exposure (reduced 
gastrointestinal and myelotoxic side-effects). In another study, Taylor et al. 
(1989) showed that liposomal disodium cromoglycate administered to healthy 
human volunteers were still detectable at 25 h, whereas an equivalent dose of 
drug inhaled as a solution was not detected within the same period. This 
investigation clearly shows the applicability of liposome-mediated pulmonary 
sustained release in humans. Nebulisation of liposomes, however, can cause 
its structural disruption with the resultant release of the encapsulated drug. 
Even at low temperatures, liposomes are unstable during storage thus limiting 
their practicality as commercial formulations (Taylor et al., 1993).  However, 
dry liposome powders containing corticosteroids have been developed for 
inhalation and they have been observed to have improved stability (Darwis 
and Kellaway, 2001). 
 
1.4.1 Biodegradable microspheres as drug delivery systems 
Microspheres are defined as homogeneous, monolithic particles measuring 
about 0.1-1000 µm and are widely used as drug carriers for controlled 
release. Microspheres have significant importance in biomedical applications 
 as the administration of drugs in the form of microspheres usually improves 
treatment through the localization of active substance at the site of action thus 
enabling prolonged drug release. Furthermore, sensitive drugs such as 
peptides and proteins may be protected against chemical and enzymatic 
degradation when entrapped in microspheres (Crotts and Park, 1997).  
 
Biodegradable microspheres produced from natural and synthetic polymers 
have been extensively investigated as drug transporters via a number of 
different routes. A number of these particles have many desirable 
characteristics for ensuring both targeted and sustained drug release. Another 
characteristic is that biodegradable microspheres can be prepared over a 
wide range of particle sizes, which is a decisive factor in the in vivo deposition 
of particulate carriers. Accordingly, biodegradable microspheres can be used 
to deliver drugs to various organs, such as the liver, the kidney, the 
reticuloendothelial system and the lungs.  
 
1.4.2 Biodegradable polymers for microspheres formulation  
A wide variety of natural and synthetic biodegradable polymers have been 
investigated for use in drug targeting or prolonged drug release. Natural 
polymers remain attractive primarily because they are natural products of 
living organisms readily available, relatively inexpensive and capable of a 
multitude of chemical modifications. The majority of investigations into the use 
of natural polymers as matrices in drug delivery systems have centered on 
proteins (e.g. collagen, gelatin, and albumin) and polysaccharides (e.g. starch, 
dextran, inulin, cellulose and hyaluronic acid) (table 1.1) (Hincal and Calis, 
 2000). Collagen has unique structural properties, therefore, it has been 
fabricated into wide variety of forms including crosslinked films, meshes, fibres 
and sponges. However, certain properties of collagen have adversely 
influenced its use as a drug delivery vehicle. These properties include poor 
dimensional stability due to swelling in vivo, poor in vivo mechanical strength 
and low elasticity, possible occurrence of an antigenic response, tissue 
irritation due to residual aldehyde crosslinking agents, and variability in drug 
release kinetics (Sinha et al., 2003). Apart from this, non-collagenous proteins 
like albumin, gelatin, casein, fibrinogen in the form of microspheres and 
nanoparticles continue to be exploited as drug delivery systems. The 
development of collagen has been some what overshadowed by advances 
made in both synthetic absorbable polymers (e.g. poly lactide and poly 
glycolide) and non-absorbable polymers such as silicone rubber and 
hydrogels. The most widely used and studied class of biodegradable polymers 
has been polyesters, including poly(lactic acid) (PLA) which was investigated 
as a drug delivery material as early as 1971,  poly(glycolic acid) (PGA), first 
marketed in 1970 as a biodegradable suture, and poly(lactide-co-glycolide) 
(PLGA). By varying the monomer ratios in polymer processing conditions, the 
resulting polymer can exhibit drug release capabilities for months or even 
years (Matschke et al., 2002). PGA is the most hydrophilic member of the poly 
(α-ester) series and is insoluble in organic solvents. In contrast, PLA is 
amorphous and more hydrophobic than PGA, owing to the extra methyl group 
in its structure (Fig 1.5) and is thus a good candidate for drug matrix release. 
It is available in the form of D(-), L(+), and racemic (DL) (Conti et al., 1992). 
Ramachandani and Robinson (1998) reported that PLGA had been  
  
 
Table 1.1.  EXAMPLES OF BIODEGRADABLE POLYMERS USED IN DRUG     
                    DELIVERY SYSTEMS 
 
               Natural polymers 
 
 
                        Synthetic polymers 
 
            (i) Animal  (ii) Plant                  (i) Animal (ii) Plant 
Proteins Polysaccharides 
 
Polysaccharid
es 
 
Proteins Polysaccharides 
 
Polysaccharides 
 
Albumin Chitin Starch Poly(lactic/gly
colic  acid) 
Poly(ε-
caprolactone) 
Polyalkylcyanoacr
ylate 
Collagen Chitosan Dextrin  Polyanhydrides  
Gelatin Hyaluronic acid   Dextran    
Fibrinoge
n 
Poly(β-
hdroxybutyric acid)    
 Alginic acid    
Casein  Poly(ortho 
esters) 
   
Fibrin      
Poly(lacti
c acid) 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
extensively used in biomaterial applications such as tracheal replacement, 
ligament reconstruction, surgical dressings, and dental repairs as well as 
functioning as transporters in drug delivery systems. Various classes of drugs 
such as anticancer agents (Hussain et al., 2002), antibiotics (Atkins et al., 
1998; Gavini et al., 2004), antimalarials (Schlicher et al., 1997), and local 
anesthetics Le Corre et al., 1997) have been incorporated into poly(lactic acid) 
or poly(lactide-co-glycolide). 
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Figure1.5. Chemical structure of (a) poly(lactic acid) and (b) poly(glycolic acid) 
(adapted from Hincal and Calis, 2000). 
 
1.4.3 Microspheres preparation 
Several processes are available for the preparation of drug-loaded, 
biodegradable microparticulates. The selection of the technique depends on 
the nature of the polymer, the drug and the intended use. In preparing for the 
controlled release microspheres, the choice of the optimal method to use is of 
utmost importance to ensure efficient entrapment of the active substance in 
 microspheres (Hincal and Calis, 2000). Some pharmaceutically acceptable 
microencapsulation techniques using hydrophobic biodegradable polymers 
such as poly(lactide-co glycolide) and  poly(lactic acid) as matrix materials for 
microspheres preparation include emulsion solvent evaporation and solvent 
extraction process, phase separation (coacervation) and spray drying (Jain, 
2000). 
 
1.4.3.1 Emulsion solvent evaporation methods 
The emulsion solvent evaporation method is the most common process for 
microspheres preparation as it is simple, reproducible and economical (Goto 
et al., 1984). The method consist of single emulsion solvent evaporation and 
double emulsion solvent evaporation procedures.  
  
1.4.3.1(a) Single emulsion solvent evaporation procedure 
 Single or simple emulsions are classified according to the nature of their 
continuous or dispersed phase, i.e. as either water-in-oil (w/o) or oil-in-water 
(o/w) emulsions. An emulsifier is present in each system (w/o or o/w) to 
stabilize the emulsion. The procedure consists of dissolving the polymer in a 
volatile organic solvent such as methylene chloride. The drug to be 
encapsulated into the microspheres is then either dissolved or suspended in 
the same solution. The mixture is then emulsified in an aqueous phase 
containing an emulsifier that does not solubilize the polymer. Various types of 
ionic surfactants e.g. sodium oleate, and non ionic surfactants e.g. Span 80, 
Tween 80, and polyvinyl alcohol are used as emulsifiers. Lipophilic (oil-
soluble, low HLB) surfactants are used to stabilized w/o emulsions whereas 
 hydrophilic (water-soluble, high HLB) surfactants are used to stabilize o/w 
emulsions. As the w/o or o/w emulsion is formed, the solvent is allowed to 
evaporate from the microparticles formed, leaving behind solid microparticles 
containing the drug.  Ultimately, the microparticles are isolated by 
centrifugation or filtration and are subsequently lyophilized (Jalil and Nixon, 
1989; Jalil and Nixon, 1990; Atkins et al., 1998).  
 
1.4.3.1(b) Double emulsion solvent evaporation procedure  
Double emulsions have promising applications in the food, cosmetic, and 
pharmaceutical industries, as well as in other fields like agriculture and 
microsphere production (van der Graaf et al., 2005). There are two main types 
of double emulsion: water-in-oil-in-water (W/O/W) emulsions, and oil-in-water-
in-oil (O/W/O) emulsion. W/O/W emulsion is more common than O/W/O 
emulsion. The technique comprises four steps: (1) primary emulsification: an 
aqueous solution of the active agent (internal water phase, W1) is emulsified 
into an organic solution containing the biodegradable polymer and lipophilic 
surfactant (oil phase, O); (2) re-emulsification: the primary emulsion (W1 / O) 
is further emulsified into a second aqueous phase containing a stabilizer 
(external water phase, W2) to form a W1/ O/ W2 double emulsion; (3) 
solidification: the organic solvent is removed by evaporation or extraction and 
solid microparticles are formed; (4) separation and purification: the 
microparticles are collected by centrifugation or filtration and are subsequently 
lyophilized (Meng et al., 2003). 
 
 
